Valentino P, Labate A, Nisticò R, Pirritano D, Cerasa A, Liguori M, Bastone L, Crescibene L, Quattrone A
Institute of Neurology, University Magna Graecia, Catanzaro, Italy.
Mult Scler. 2009 Jan;15(1):114-5. doi: 10.1177/1352458508096685. Epub 2008 Oct 9.
The aim of this study was to correlate the brain atrophy with serum levels of anti-GM1 antibodies in patients with relapsing-remitting multiple sclerosis (RRMS).
Plasma sample from 52 patients with RRMS and 65 healthy controls were examined for anti-GM1 antibodies. Patients with RRMS underwent to MRI study with automated method called SIENAX that calculated an estimate of gray matter (GM(V)) and white matter (WM(V)) volumes.
The percentage of RRMS patients with increased anti-GM1 was 37.8%. Elevated levels of anti-GM1 antibodies did not correlate with brain atrophy.
Anti-GM1 antibodies do not represent a marker of axonal damage in patients with RRMS.
本研究旨在探讨复发缓解型多发性硬化症（RRMS）患者脑萎缩与血清抗GM1抗体水平之间的相关性。
检测了52例RRMS患者和65名健康对照者的血浆样本中的抗GM1抗体。RRMS患者接受了名为SIENAX的自动化MRI研究，该研究计算了灰质（GM(V)）和白质（WM(V)）体积的估计值。
抗GM1升高的RRMS患者比例为37.8%。抗GM1抗体水平升高与脑萎缩无关。
抗GM1抗体并非RRMS患者轴索损伤的标志物。
